Those come on top of compensation already paid by Servier to victims ... which was approved for diabetes but widely used as an appetite suppressant. It was eventually withdrawn from sale in ...

Servier is on course to get a return on its $1.8 billion takeover of Agios Pharma's oncology business after getting a key FDA approval for Tibsovo, the main asset in the deal. The US regulator has ...